December 20, 2017 / 1:10 PM / 6 months ago

BRIEF-AbbVie's Upadacitinib Shows Positive Results As Monotherapy In Phase 3 Rheumatoid Arthritis Study

* ABBVIE'S UPADACITINIB SHOWS POSITIVE RESULTS AS MONOTHERAPY IN PHASE 3 RHEUMATOID ARTHRITIS STUDY, MEETING ALL PRIMARY AND KEY SECONDARY ENDPOINTS

* ABBVIE INC - LOOK FORWARD TO SHARING ADDITIONAL DATA FROM UPADACITINIB PHASE 3 RHEUMATOID ARTHRITIS PROGRAM WITH SCIENTIFIC COMMUNITY IN 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below